Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

about

A safety evaluation of raltegravir for the treatment of HIV.Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.

P2860

Q47377203-9A017460-8C15-433D-893C-C128F0D24F90 Q50086057-213AD961-F497-46D2-89B0-E5321FC7EF84

P2860

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

Item

http://www.wikidata.org/entity/Q40492253

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

@en

type

Item

label

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

@en

prefLabel

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

@en

P1476

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

@en

P2093

Chandni Valiathan

http://www.w3.org/2001/XMLSchema#string

Crystal Bethel-Brown

http://www.w3.org/2001/XMLSchema#string

Helen Manthos

http://www.w3.org/2001/XMLSchema#string

John Brejda

http://www.w3.org/2001/XMLSchema#string

Julie Ann Luk

http://www.w3.org/2001/XMLSchema#string

Kathleen Deschamps

http://www.w3.org/2001/XMLSchema#string

Lilly East

http://www.w3.org/2001/XMLSchema#string

Michael Gartner

http://www.w3.org/2001/XMLSchema#string

Patrick Larson

http://www.w3.org/2001/XMLSchema#string

Rajesh Krishna

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

P304

533-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BDD.2043

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27696440

http://www.w3.org/2001/XMLSchema#string

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

about

P2860

P2860

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698